Concepedia

Author

Tarek Meniawy

Sir Charles Gairdner HospitalORCID

Also Known As

Bo Gao, Meniawy, Tarek, Meniawy, Tarek M, Meniawy,Tarek, Michael Friedlander, T M Meniawy, T. M. Meniawy, T. Meniawy, T.M. Meniawy, Tarek M Meniawy

176

Publications

4.5K

Citations

34

H-Index

50

Concepts

All Affiliations

Sir Charles Gairdner HospitalThe University of Western AustraliaEdith Cowan UniversityPeter MacCallum Cancer CentreLinear Clinical Research
TM

About

Tarek Meniawy is an author at Sir Charles Gairdner Hospital specializing in oncology, medicine, and radiation oncology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

21

27

2.1K

2

Immunology

14

16

1.4K

3

Health Sciences

5

5

112

4

Cell Biology

4

4

159

5

Engineering

2

2

68

Tarek Meniawy

×

62

Publications

3.6K

Citations

32

H-Index

YearCitations

Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b study

Jeffrey S. Weber, Matteo S. Carlino, Adnan Khattak,

The Lancet

2024

598

Circulating tumor DNA to monitor treatment response and detect acquired resistance in patients with metastatic melanoma

Elin S. Gray, Helen Rizos, Anna Reid,

Oncotarget

2015

322

Adjuvant nivolumab in resected stage IIB/C melanoma: primary results from the randomized, phase 3 CheckMate 76K trial

John M. Kirkwood, Michele Del Vecchio, Jeffrey S. Weber,

Nature Medicine

2023

174

Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial

Jacobus Pfisterer, Catherine Shannon, Klaus Baumann,

The Lancet Oncology

2020

157

A Novel Clinical Prediction Model for Prognosis in Malignant Pleural Mesothelioma Using Decision Tree Analysis

Fraser Brims, Tarek Meniawy, Ian Duffus,

Journal of Thoracic Oncology

2016

156

Comparison of fibulin-3 and mesothelin as markers in malignant mesothelioma

Jenette Creaney, Ian M. Dick, Tarek Meniawy,

Thorax

2014

144

Clinical activity of durvalumab for patients with advanced mismatch repair-deficient and repair-proficient endometrial cancer. A nonrandomized phase 2 clinical trial

Yoland Antill, Peey‐Sei Kok, Kristy Robledo,

Journal for ImmunoTherapy of Cancer

2021

120

Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial

Michael Friedländer, Tarek Meniawy, Ben Markman,

The Lancet Oncology

2019

113

Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients

Ashleigh C. McEvoy, Lydia Warburton, Zeyad Al‐Ogaili,

BMC Cancer

2018

98

Safety, Tolerability, and Potential Clinical Activity of a Glucocorticoid-Induced TNF Receptor–Related Protein Agonist Alone or in Combination With Nivolumab for Patients With Advanced Solid Tumors

Kimberley M. Heinhuis, Matteo S. Carlino, Markus Joerger,

JAMA Oncology

2019

90

Page 1